ProCE Banner Activity

PURPOSE 1: Lenacapavir PrEP in Adolescent Cisgender Women

Conference Coverage
Slideset

In phase III PURPOSE 1 trial, lenacapavir was safe and well tolerated in adolescents, with plasma concentrations comparable to those in adults, and resulted in zero HIV infections.

Released: March 14, 2025

Expiration: September 13, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare